Redhill Biopharma Return on Equity

Redhill Biopharma (RDHL) currently reports a ROE of -218.21%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Redhill Biopharma's ROE history and peer comparisons.

Redhill Biopharma's ROE of -218.21% is lower than the Healthcare sector average of 22.76%. That is roughly 1058.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Redhill Biopharma's current -218.21% should be judged against Healthcare norms (sector average: 22.76%) and against RDHL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -218.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Redhill Biopharma, and consider following RDHL for alerts when major investors trade the stock.

Redhill Biopharma is classified in the Healthcare sector. On ROE, it currently shows -218.21% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RDHL with unrelated industries.